Medtronic’s next generation spinal cord stimulator cleared by FDA

Medtronic's latest spinal cord stimulation system for the treatment of chronic intractable pain has been cleared by FDA.

The world's smallest SCS, the Intellis device offers activity tracking and personalized pain relief. 

It is designed to surmount limitations of current SCS devices, and comprises an implantable neurostimulator that records patient activity around the clock, a patient programmer and recharger. A physician manages the treatment on a Samsung tablet that allows the wireless programming of stimulation.

Dr. Dave Rhew, chief medical officer and head of healthcare and fitness for Samsung Electronics America said, "We are excited to partner with Medtronic in their aim to simplify programming, and streamline therapy management with the Intellis platform. Samsung's Galaxy tablets-secured by the HIPAA-ready Samsung Knox mobile security platform-will support future Medtronic therapies and over the air (OTA) software upgrades to ensure clinicians using Intellis have access to the most up-to-date solutions." 

Dr. Lance Roy, a pain medicine specialist at Duke University Medical Center, in a statement said, "Chronic pain is challenging to manage. Having real-time data can provide more information about patients' quality of life changes. This platform represents a welcome new option for managing some kinds of chronic pain. New non-opioid treatment options are important given the national crisis related to opioid abuse."